The short answer: cartilage damage that hasn't responded to conservative care

For most patients researching ChondroFiller, the deciding question is a practical one: have you already tried the conventional routes — physiotherapy, anti-inflammatory medication, or earlier injection therapy — and still not found adequate relief? If imaging confirms cartilage damage is the underlying cause, that combination of treatment-resistant symptoms and MRI evidence is the typical starting point for a candidate assessment.

ChondroFiller is an injectable collagen scaffold delivered under ultrasound guidance as an outpatient procedure. Its mechanism is acellular matrix-induced chondrogenesis: rather than introducing donor or laboratory-grown tissue, the scaffold recruits the patient's own progenitor cells to support the body's natural repair processes. There is no fixed upper age limit, and candidacy is not determined by symptom severity alone — two patients with similar pain levels may be triaged very differently depending on what their MRI shows about the pattern and extent of cartilage wear. Suitability is confirmed at a consultant-led assessment, not through a self-referral checklist.

Conditions most commonly assessed for ChondroFiller

Several distinct clinical presentations bring patients to a ChondroFiller assessment, though they share a common thread: structural cartilage damage that imaging has confirmed.

• Osteoarthritis (Kellgren-Lawrence Grade III–IV) is the most frequent indication. At this stage, wear tends to be diffuse — affecting a broad area of joint surface rather than a single contained lesion. The collagen scaffold suits this pattern because it coats the joint surface as an additive protective layer and supports endogenous repair across the whole worn area, without restriction by defect size.
• Post-traumatic cartilage damage — arising after a significant joint injury, including meniscal tears or ligament injuries that involve secondary cartilage damage — is a recognised route to candidacy. The structural disruption left behind can persist long after the original injury, making this a distinct presentation in its own right.
• Age-related degeneration and overuse-related breakdown are also assessed, even when no single traumatic episode triggered the problem. Gradual cartilage thinning from repetitive load or natural ageing constitutes a qualifying presentation.
• Chronic inflammation-driven cartilage loss may be considered, though the published evidence is stronger for osteoarthritis and post-traumatic presentations than for inflammatory arthritis subtypes. Eligibility in that subgroup should not be assumed and is subject to individual assessment.

Across all four presentations, the shared entry threshold is the same: conservative measures — physiotherapy, medication, earlier injections — have not provided adequate, lasting relief, and structural cartilage damage is confirmed on imaging. ChondroFiller is not a first-line treatment.

Why MRI findings — not symptoms — decide suitability

Pain scores and symptom questionnaires tell the clinical team how much a joint is affecting daily life; they do not reveal the wear pattern that actually determines which treatment is appropriate.

Two patients can present with comparable pain and functional limitation yet be directed to entirely different treatment routes. When MRI shows a small, contained focal defect with healthy cartilage borders, the clinical picture points toward a targeted approach for that site. When MRI reveals diffuse, widespread surface wear — the pattern typical of Kellgren-Lawrence Grade III–IV osteoarthritis — the whole-surface ChondroFiller injection pathway is the better fit, because it coats the joint surface as a protective layer rather than addressing a single bounded lesion. At MSK Doctors, imaging review is supported by onMRI™, an AI-assisted analysis tool that helps characterise cartilage wear patterns alongside the consultant's own assessment, rather than replacing it.

MRI also identifies bone-on-bone end-stage joint destruction, where the clinical picture changes substantially — that finding is addressed in the following section.

Because suitability turns on imaging rather than symptom description, patients can arrange an assessment directly — without a GP referral — to establish where they stand on the basis of their own scan.

Which joints are treated and whether age is a barrier

Both questions — which joints qualify, and whether age rules anyone out — have clear, practical answers.

ChondroFiller injection is used across the knee, hip, and ankle, where the published evidence base is deepest, and extends to the shoulder, elbow, wrist, and smaller joints of the hand and foot. For upper-limb indications, clinical use is supported by post-traumatic wrist data from the Matta et al. study, which confirmed technical feasibility and favourable MRI findings — including reduced bone marrow oedema and widening of the joint space — following cartilage damage associated with distal radius fracture repair. That said, the evidence for shoulder, elbow, and wrist candidacy is less extensive than for lower-limb joints, and this is worth discussing openly during assessment.

On age: there is no upper age ceiling. The scaffold acts as a whole-surface mechanical cushion and supports acellular matrix-induced chondrogenesis — recruiting the patient's own progenitor cells across the joint surface rather than depending on a focused regenerative response at a specific site. That mechanism does not require a young or biologically vigorous joint to function, which is why patients with Kellgren-Lawrence Grade III–IV osteoarthritis are not excluded on age grounds alone. Younger, biologically active patients may derive stronger regenerative benefit from the scaffold's capacity to support endogenous repair, but advanced age is not a disqualifying criterion.

When ChondroFiller injection is not the right option

Eligibility boundaries exist, and it is worth knowing the main ones before attending an assessment.

The clearest contraindication is end-stage, bone-on-bone joint destruction — where imaging confirms no viable cartilage surface or perilesional tissue remains. The scaffold depends on surviving tissue to integrate and support cell migration; when that structural environment is absent, the treatment cannot fulfil its intended role. Patients in this category are typically counselled toward joint replacement rather than a scaffold-based approach.

Beyond that primary exclusion, no formal BMI threshold or comprehensive contraindication list for inflammatory arthritis subtypes has been established in published clinical guidance. Patients with complex systemic conditions — including certain inflammatory arthritis diagnoses — should raise these specifics directly at assessment, where individual history and imaging can be weighed together.

Realistic expectations about rehabilitation also play a role. Guided physiotherapy after the injection is part of the treatment plan, and patients who are unable to engage with post-injection rehabilitation may not achieve the outcomes the evidence supports.

Those caveats noted, the majority of patients presenting with Kellgren-Lawrence Grade III–IV osteoarthritis and structurally confirmed cartilage damage are assessed positively for the injection pathway.

What candidates can realistically expect from treatment

Published clinical data give confirmed candidates a reasonably clear picture of what to expect. In the Jerosch et al. post-market clinical follow-up study, IKDC scores improved by a mean of 32.4 points at three years — more than double the 16.7-point minimum clinically important difference, meaning the gain translates to a noticeable change in daily function rather than a marginal shift on a scoring chart. On the structural side, MRI-based MOCART scores reached 81.6–84.3 at one year, indicating good scaffold integration and over 80% defect filling — this is a quality measure of how well the collagen matrix has incorporated into the joint, not a pain score.

Complication rates in the clinical evidence approach 0%. Reoperation rates are reported at approximately 3–8%, which is low relative to staged cell-based procedures such as ACI or MACI (where reoperation rates of up to 37% have been documented), though it does mean a minority of patients will require further treatment and should factor that into their decision.

For patients who cannot commit to multi-stage surgical procedures, or who have been advised they are not candidates for open cartilage surgery, the single outpatient injection pathway offers a practical route to treatment without a theatre admission.

Outcomes are not uniform: patients with more advanced joint destruction at baseline tend to have a lower ceiling for functional improvement, and rehabilitation compliance after the injection influences how well the repair process progresses. Individual results should be discussed at a consultant assessment — you can book without a referral at mskdoctors.com.